• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,993.13 806.26
( 1.04%)
Global Indices
Nasdaq
52,569.33 -110.31
(-0.21%)
Dow Jones
7,555.54 -37.86
(-0.50%)
Hang Seng
66,873.37 -1,878.14
(-2.73%)
Nikkei 225
10,555.24 39.32
(0.37%)
Forex
USD-INR
96.26 0.11
(0.12%)
EUR-INR
110.12 0.41
(0.38%)
GBP-INR
129.49 0.88
(0.69%)
JPY-INR
0.59 0.00
(0.14%)

EQUITY - MARKET SCREENER

Orchid Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524372
INE191A01027
270.1445747
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ORCHPHARMA
105.96
5487.3
EPS(TTM)
Face Value()
Div & Yield %
10.21
10
0
 

p h capital ltd
Lupin receives EMA approval for Pediatric Indication of NaMuscla
Jul 01,2026
Lupin today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6¨C11 years, weighing at least 20 kg), adolescents (12¨C17 years), and adults (¡Ý18 years) with non-dystrophic myotonic disorder.